Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal‐F1)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal‐F1)

Published:2013-10-24 Issue:2 Volume:31 Page:176-184
ISSN:0742-3071
Container-title:Diabetic Medicine
language:en
Short-container-title:Diabet. Med.

Author:

Bolli G. B.¹,Munteanu M.²,Dotsenko S.³,Niemoeller E.⁴,Boka G.⁵,Wu Y.⁶,Hanefeld M.⁷

Affiliation:

1. University of Perugia Perugia Italy

2. University of Medicine and Pharmacy ‘Victor Babes’ Timisoara Romania

3. Zaporozhye State Medical University Zaporozhye Ukraine

4. Sanofi R&D Frankfurt Germany

5. Sanofi R&D Chilly‐Mazarin France

6. Sanofi R&D Bridgewater NJ USA

7. Centre for Clinical Studies GWT‐TUD GmbH Dresden Germany

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dme.12328

Reference26 articles.

1. Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy

2. Statement by an American Association of Clinical Endocrinologists/ American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control

3. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

4. The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review

Cited by 106 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systematic review of the efficacy and safety of GLP-1 receptor agonists in the treatment of patients with type 2 diabetes mellitus;Pharmacia;2024-08-02

2. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists;Frontiers in Endocrinology;2024-07-24

3. The effect of subcutaneous Lixisenatide on weight loss in patients with type 2 Diabetes Mellitus: Systematic review and Meta-Analysis of randomized controlled trials;Diabetes Research and Clinical Practice;2024-04

4. Non‐insulin Parenteral Therapies;Textbook of Diabetes;2024-01-12

5. Inkretin-Agonisten: In 30 Jahren vom Geheimtipp zum Bestseller;Deutsches Ärzteblatt Online;2023-11-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3